Last reviewed · How we verify
AZD7442
AZD7442 is a combination of two monoclonal antibodies that bind to the SARS-CoV-2 spike protein to neutralize the virus and provide passive immunity.
AZD7442 is a combination of two monoclonal antibodies that bind to the SARS-CoV-2 spike protein to neutralize the virus and provide passive immunity. Used for Prevention of COVID-19 in adults and adolescents with inadequate immune response to vaccination, Treatment of mild-to-moderate COVID-19 in high-risk patients.
At a glance
| Generic name | AZD7442 |
|---|---|
| Also known as | Combination of 2 mAbs (AZD8895 and AZD1061), Combination of 2mAbs(AZD8895 and AZD1061), AZD8895 + AZD1061, A combination of 2 mAbs (AZD8895 and AZD1061), Evusheld |
| Sponsor | AstraZeneca |
| Drug class | Monoclonal antibody combination |
| Target | SARS-CoV-2 spike protein receptor-binding domain |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
AZD7442 consists of two engineered human monoclonal antibodies (tixagevimab and cilgavimab) that target non-overlapping epitopes on the SARS-CoV-2 spike protein receptor-binding domain. These antibodies work synergistically to neutralize the virus and prevent viral entry into host cells. The antibodies are engineered with extended half-lives to provide prolonged protection against COVID-19.
Approved indications
- Prevention of COVID-19 in adults and adolescents with inadequate immune response to vaccination
- Treatment of mild-to-moderate COVID-19 in high-risk patients
Common side effects
- Injection site reactions
- Headache
- Fatigue
- Myalgia
Key clinical trials
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) (PHASE2)
- Clinical Use of EVUSHELD as Pre-exposure Prophylaxis in Real-world Setting in Gulf Cooperation Council Countries
- AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics (PHASE1)
- Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study (PHASE2, PHASE3)
- AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) (PHASE3)
- eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health Services
- Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. (PHASE3)
- Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD7442 CI brief — competitive landscape report
- AZD7442 updates RSS · CI watch RSS
- AstraZeneca portfolio CI